Back to Search
RUBEN NIESVIZKY, MD
MD
Hematology & Oncology Physician
NPI: 1710074885IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
195309(NY)
Education
OTHER
Class of 1985
Research & Publications (20)
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma.
PMID 18673366·Br J Haematol·2008
8-other
Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies.
PMID 18349031·Ann Oncol·2008
8-other
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.
PMID 17989313·Blood·2008
3-trial
Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma.
PMID 18067007·Leuk Lymphoma·2007
8-other
Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy.
PMID 17686058·Br J Haematol·2007
3-trial
Gallium nitrate in multiple myeloma: prolonged survival in a cohort of patients with advanced-stage disease.
PMID 12776256·Semin Oncol·2003
6-review
Impact of early response to sequential high-dose chemotherapy on outcome of patients with advanced myeloma and poor prognostic features.
PMID 12002766·Leuk Lymphoma·2002
3-trial
International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma.
PMID 19421229·Leukemia·2009
6-review
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation.
PMID 19494840·Leukemia·2009
6-review
Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma.
PMID 19545290·Br J Haematol·2009
8-other
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).
PMID 19554029·Leukemia·2009
6-review
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.
PMID 19561323·Blood·2009
8-other
Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma.
PMID 19373653·Leuk Lymphoma·2009
3-trial
CDK2 phosphorylation of Smad2 disrupts TGF-beta transcriptional regulation in resistant primary bone marrow myeloma cells.
PMID 19201832·J Immunol·2009
8-other
Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma.
PMID 19302559·Eur J Haematol·2009
3-trial
Milatuzumab: a promising new agent for the treatment of lymphoid malignancies.
PMID 19053886·Expert Opin Investig Drugs·2009
6-review
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.
PMID 19626046·Leukemia·2009
8-other
Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma.
PMID 19671864·Clin Cancer Res·2009
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 425 E 61ST ST FL 8
NEW YORK, NY 10065 - Phone
- (646) 962-6500
Quick Facts
- NPI
- 1710074885
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 41
- Publications
- 20
Are you this provider?
Claim Your Profile